Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Phase 1/2
60
about 4.6 years
18–120
1 site in MD
What this study is about
This trial is testing a new treatment for advanced or metastatic endometrial cancer. It combines an AdHER2DC vaccine, Lenvatinib, N-803, and Pembrolizumab with HER2 targeting. The treatment involves giving the vaccine under the skin, taking a tablet by mouth daily, and receiving injections of other drugs.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AdHER2DC vaccine
- 2.Receive N-803
- 3.Receive Pembrolizumab
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
vaccine, lenvatinib, Antineoplastic Agent [TC] (Cytokine Receptor Superfamily Interactions), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
injection, oral (Oral Capsule), infusion
Oncology